ZOLL

ZOLL Medical Corporation, founded in 1980 by Dr. Paul Zoll, is a Massachusetts-based manufacturer of medical devices and software solutions. In 2012, the company was acquired by the Japanese conglomerate Asahi Kasei for $2.21 billion and operates as its subsidiary.

ZOLL focuses on acute critical care and related diagnostics. Its primary domains include resuscitation, temperature management, and sleep apnea diagnosis. The company sells its devices to hospitals, emergency medical services (EMS) providers, and home care patients.

The company develops professional defibrillators (such as the X Series and R Series) and automated external defibrillators (AEDs) for public and medical use. Another key product is the LifeVest, a wearable defibrillator for patients at risk of sudden cardiac arrest. Additionally, ZOLL manufactures ventilators and the WatchPAT home sleep apnea diagnostic device.

ZOLL competes globally with medical technology firms like Stryker (which acquired Physio-Control) and Philips in the resuscitation and critical care markets. In the sleep apnea diagnostics space, it competes with companies such as ResMed.

ZOLL maintains a significant R&D and operational footprint in Israel, built primarily through acquisitions. In 2015, ZOLL acquired Kfar Saba-based Kyma Medical Technologies to integrate its RF-based fluid monitoring technology for heart failure patients. In 2021, the company expanded its Israeli operations by acquiring Caesarea-based Itamar Medical for approximately $538 million. The Caesarea site continues to serve as a key center for ZOLL's sleep diagnostic operations and development of the WatchPAT device.